Search trials



Primary RegistryProtocol numberPublic titleScientific titleType of studyRecruitment statusLast updated
LBCTR2019030200RTH258B2302A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaA Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular EdemaInterventionalComplete20/02/2019
LBCTR2020023394CLNP023X2203Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients InterventionalOther31/01/2020
LBCTR20211249344202-HEM-301An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell DiseaseAn Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell DiseaseInterventionalRecruiting10/12/2021
LBCTR2020030215MS700568_0026Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple SclerosisAn Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical TrialsObservationalComplete11/06/2021
LBCTR2021034759MRX-503An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)InterventionalOther03/03/2021
LBCTR2020043495Solidarity-Lebanon2020An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of careInterventionalPending22/04/2020
LBCTR2019080216GBT440-034Study to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031An Open Label Extension Study of GBT440 Administered Orally to Patients With Sickle Cell Disease Who Have Participated in GBT440 Clinical TrialsInterventionalOther27/03/2019
LBCTR2019070220PTG300-03An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia SubjectsAn Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia SubjectsInterventionalComplete03/04/2019
LBCTR2022055038CABL001A2001BAn Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued TreatmentAn Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued TreatmentInterventionalComplete06/05/2022
LBCTR2020011375CICL670E2419THETIS- Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia InterventionalComplete01/01/2020
items per page101 - 110 of 174 items